Lepak A - Search Results

1

Model-Informed Drug Development for Anti-Infectives: State of the Art and Future.

Rayner CR, Smith PF, Andes D, Andrews K, Derendorf H, Friberg LE, Hanna D, Lepak A, Mills E, Polasek TM, Roberts JA, Schuck V, Shelton MJ, Wesche D, Rowland-Yeo K. Rayner CR, et al. Among authors: lepak a. Clin Pharmacol Ther. 2021 Apr;109(4):867-891. doi: 10.1002/cpt.2198. Epub 2021 Mar 9. Clin Pharmacol Ther. 2021. PMID: 33555032 Free PMC article. Review.

2

A simple approach for estimating gene expression in Candida albicans directly from a systemic infection site.

Andes D, Lepak A, Pitula A, Marchillo K, Clark J. Andes D, et al. Among authors: lepak a. J Infect Dis. 2005 Sep 1;192(5):893-900. doi: 10.1086/432104. Epub 2005 Jul 25. J Infect Dis. 2005. PMID: 16088840

3

Time course of microbiologic outcome and gene expression in Candida albicans during and following in vitro and in vivo exposure to fluconazole.

Lepak A, Nett J, Lincoln L, Marchillo K, Andes D. Lepak A, et al. Antimicrob Agents Chemother. 2006 Apr;50(4):1311-9. doi: 10.1128/AAC.50.4.1311-1319.2006. Antimicrob Agents Chemother. 2006. PMID: 16569846 Free PMC article.

4

Impact of antimicrobial dosing regimen on evolution of drug resistance in vivo: fluconazole and Candida albicans.

Andes D, Forrest A, Lepak A, Nett J, Marchillo K, Lincoln L. Andes D, et al. Among authors: lepak a. Antimicrob Agents Chemother. 2006 Jul;50(7):2374-83. doi: 10.1128/AAC.01053-05. Antimicrob Agents Chemother. 2006. PMID: 16801415 Free PMC article.

5

In vivo fluconazole pharmacodynamics and resistance development in a previously susceptible Candida albicans population examined by microbiologic and transcriptional profiling.

Andes D, Lepak A, Nett J, Lincoln L, Marchillo K. Andes D, et al. Among authors: lepak a. Antimicrob Agents Chemother. 2006 Jul;50(7):2384-94. doi: 10.1128/AAC.01305-05. Antimicrob Agents Chemother. 2006. PMID: 16801416 Free PMC article.

6

Time course global gene expression analysis of an in vivo Candida biofilm.

Nett JE, Lepak AJ, Marchillo K, Andes DR. Nett JE, et al. J Infect Dis. 2009 Jul 15;200(2):307-13. doi: 10.1086/599838. J Infect Dis. 2009. PMID: 19527170 Free PMC article.

7

In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species.

Andes D, Diekema DJ, Pfaller MA, Bohrmuller J, Marchillo K, Lepak A. Andes D, et al. Among authors: lepak a. Antimicrob Agents Chemother. 2010 Jun;54(6):2497-506. doi: 10.1128/AAC.01584-09. Epub 2010 Apr 12. Antimicrob Agents Chemother. 2010. PMID: 20385855 Free PMC article.

8

Fungal sepsis: optimizing antifungal therapy in the critical care setting.

Lepak A, Andes D. Lepak A, et al. Crit Care Clin. 2011 Jan;27(1):123-47. doi: 10.1016/j.ccc.2010.11.001. Crit Care Clin. 2011. PMID: 21144990 Review.

9

Antifungal PK/PD considerations in fungal pulmonary infections.

Lepak AJ, Andes DR. Lepak AJ, et al. Semin Respir Crit Care Med. 2011 Dec;32(6):783-94. doi: 10.1055/s-0031-1295726. Epub 2011 Dec 13. Semin Respir Crit Care Med. 2011. PMID: 22167406 Review.

10

Editorial commentary: Antifungal therapeutic drug monitoring progress: getting it right the first time.

Andes D, Lepak A. Andes D, et al. Among authors: lepak a. Clin Infect Dis. 2012 Aug;55(3):391-3. doi: 10.1093/cid/cis446. Epub 2012 May 18. Clin Infect Dis. 2012. PMID: 22610924 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

83 results

Search Page

Filters